Antiangiogenic and antitumor effects of IMMUNEPOTENT CRP in murine melanoma

References

• Franco-Molina, M.A., Mendoza-Gamboa, E., Miranda-Hernández, D., Zapata-Benavides, P., Castillo-León, L., Isaza-Brando, C., Tamez-Guerra, R.S., Rodríguez-Padilla, C. In vitro effects of bovine dialyzable leukocyte extract (bDLE) in cancer cells. Cytotherapy 2006, 8, 408–414.
   PubMed Web of Science ®Google Scholar
• Franco-Molina, M.A., Mendoza-Gamboa, E., Castillo-León, L., Tamez-Guerra, R.S., Rodríguez-Padilla, C. Bovine dialyzable leukocyte extract protects against LPS-induced, murine endotoxic shock. Int. Immunopharmacol. 2004, 4, 1577–1586.
   PubMed Web of Science ®Google Scholar
• Pilotti, V., Mastrorilli, M., Pizza, G., De Vinci C., Busutti, L., Palareti, A., Gozzetti, A., Cavallari, G., Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 1996, 9, 117–121.
   PubMedGoogle Scholar
• Franco-Molina, M.A., Mendoza-Gamboa, E., Zapata-Benavides, P., Vera-García, M.E., Castillo-Tello, P., García de la Fuente, A., Mendoza, R.D., Garza, R.G., Tá,mez-Guerra, R.S., Rodríguez-Padilla, C. IMMUNEPOTENT CRP (bovine dialyzable leukocyte extract) adjuvant immunotherapy: a phase I study in non-small cell lung cancer patients. Cytotherapy 2008, 10, 490–496.
   PubMed Web of Science ®Google Scholar
• Pizza, G., De Vinci C., Cuzzocrea, D., Menniti, D., Aiello, E., Maver, P., Corrado, G., Romagnoli, P., Dragoni, E., LoConte, G., Riolo, U., Palareti, A., Zucchelli, P., Fornarola, V., Viza, D., A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer. Biotherapy 1996, 9, 123–132.
   PubMedGoogle Scholar
• Mendoza-Gamboa, E., Franco-Molina, M.A., Zapata-Benavides, P., Castillo-Tello, P., Vera-García, M.E., Tamez-Guerra, R.S., Rodríguez-Padilla, C. Bovine dialyzable leukocyte extract modulates AP-1 DNA-binding activity and nuclear transcription factor expression in MCF-7 breast cancer cells. Cytotherapy 2008, 10, 212–219.
   PubMed Web of Science ®Google Scholar
• Shabbits, J.A., Hu, Y., Mayer, L.D. Tumor chemosensitization strategies based on apoptosis manipulations. Mol. Cancer Ther. 2003, 2, 805–813.
   PubMed Web of Science ®Google Scholar
• Choi, C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005, 5, 30.
   PubMed Web of Science ®Google Scholar
• Roninson, IB. Tumor Cell Senescence in Cancer Treatment. Cancer Res 2003, 63: 2705–2715.
   PubMed Web of Science ®Google Scholar
• Ledezma, E., Apitz-Castro, R., Cardier, J. Apoptotic and anti-adhesion effect of ajoene, a garlic derived compound, on the murine melanoma B16F10 cells: possible role of caspase-3 and the alpha(4)beta(1) integrin. Cancer Lett. 2004, 206, 35–41.
   PubMed Web of Science ®Google Scholar
• Gude, R.P., Jadhav, M.G., Rao, S.G., Jagtap, A.G. Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model. Cancer Biother. Radiopharm. 2002, 17, 183–192.
   PubMed Web of Science ®Google Scholar
• Malafa, M.P., Fokum, F.D., Smith, L., Louis, A. Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate. Ann. Surg. Oncol. 2002, 9, 1023–1032.
   PubMedGoogle Scholar
• Balch, C.M., Soong, S.J., Gershenwald, J.E., Thompson, J.F., Reintgen, D.S., Cascinelli, N., Urist, M., McMasters, K.M., Ross, M.I., Kirkwood, J.M., Atkins, M.B., Thompson, J.A., Coit, D.G., Byrd, D., Desmond, R., Zhang, Y., Liu, P.Y., Lyman, G.H., Morabito, A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 2001, 19, 3622–3634.
   PubMed Web of Science ®Google Scholar
• Hormbrey, E., Gillespie, P., Turner, K., Han, C., Roberts, A., McGrouther, D., Harris, A.L. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin. Exp. Metastasis 2002, 19, 651–663.
   PubMed Web of Science ®Google Scholar
• Werther, K., Christensen, I.J., Nielsen, H.J. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand. J. Clin. Lab. Invest. 2002, 62, 343–350.
   PubMed Web of Science ®Google Scholar
• Salven, P., Orpana, A., Joensuu, H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin. Cancer Res. 1999, 5, 487–491.
   PubMed Web of Science ®Google Scholar
• Verheul, H.M., Lolkema, M.P., Qian, D.Z., Hilkes, Y.H., Liapi, E., Akkerman, J.W., Pili, R., Voest, E.E. Platelets take up the monoclonal antibody bevacizumab. Clin. Cancer Res. 2007, 13, 5341–5347.
   PubMed Web of Science ®Google Scholar
• Hanrahan, E.O., Ryan, A.J., Mann, H., Kennedy, S.J., Langmuir, P., Natale, R.B., Herbst, R.S., Johnson, B.E., Heymach, J.V. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin. Cancer Res. 2009, 15, 3600–3609.
   PubMed Web of Science ®Google Scholar
• Patruno, R., Arpaia, N., Gadaleta, C.D., Passantino, L., Zizzo, N., Misino, A., Lucarelli, N.M., Catino, A., Valerio, P., Ribatti, D., Ranieri, G. VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. J. Cell. Mol. Med. 2009, 13, 555–561.
   PubMed Web of Science ®Google Scholar
• Molhoek, KR., Griesemann, H., Shu, J., Gershenwald, JE., Brautigan, DL., Slingluff CL, Jr. Human melanoma cytolysis by combined inhibition target of rapamycin and vascular endothelial growth vascular endothelial growth factor receptor-2. Cancer Res. 2008;68:4392–4397.
   PubMedGoogle Scholar